These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 19435402

  • 1. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
    Pergolizzi JV, Mercadante S, Echaburu AV, Van den Eynden B, Fragoso RM, Mordarski S, Lybaert W, Beniak J, Orońska A, Slama O, Euromed Communications meeting.
    Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
    [Abstract] [Full Text] [Related]

  • 2. Transdermal buprenorphine in cancer pain and palliative care.
    Sittl R.
    Palliat Med; 2006 Jun; 20 Suppl 1():s25-30. PubMed ID: 16764218
    [Abstract] [Full Text] [Related]

  • 3. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R, Kayser H, Sittl R.
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [Abstract] [Full Text] [Related]

  • 4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 5. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N, Sittl R, Likar R.
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [Abstract] [Full Text] [Related]

  • 6. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J, Sittl R.
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I.
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [Abstract] [Full Text] [Related]

  • 8. Transdermal buprenorphine in the treatment of chronic pain.
    Sittl R.
    Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664
    [Abstract] [Full Text] [Related]

  • 9. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV.
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [Abstract] [Full Text] [Related]

  • 10. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R, Likar R, Nautrup BP.
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [Abstract] [Full Text] [Related]

  • 11. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies.
    Louis F.
    Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980
    [Abstract] [Full Text] [Related]

  • 12. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R, Nuijten M, Nautrup BP.
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [Abstract] [Full Text] [Related]

  • 13. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A.
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [Abstract] [Full Text] [Related]

  • 14. Buprenorphine TDS: use in daily practice, benefits for patients.
    Radbruch L.
    Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
    [Abstract] [Full Text] [Related]

  • 15. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K.
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [Abstract] [Full Text] [Related]

  • 17. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
    Mercadante S, Villari P, Ferrera P, Casuccio A.
    Eur J Pain; 2006 Feb; 10(2):153-9. PubMed ID: 16310719
    [Abstract] [Full Text] [Related]

  • 18. Buprenorphine TDS: the clinical development rationale and results.
    Radbruch L, Vielvoye-Kerkmeer A.
    Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119
    [Abstract] [Full Text] [Related]

  • 19. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO, Bryuzgin V, Kourteva G, FEN-INT-20 Study Group.
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [Abstract] [Full Text] [Related]

  • 20. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW.
    Curr Med Res Opin; 2003 Mar; 19(6):457-69. PubMed ID: 14594516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.